Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.
Jui-Feng HsuYen-Lung LeeHsu-Liang ChangPo-Ju WeiYu-Ting ShenChi-Min LinChing-Yi LiInn-Wen ChongChih-Jen YangPublished in: Asia-Pacific journal of clinical oncology (2019)
Aggressive treatment for lung cancer with malignant ascites is encouraged when possible. Bevacizumab-based treatment may serve as one effective treatment strategy for non-squamous cell lung carcinoma with malignant ascites. Further prospective trials are urgently needed.